Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12445518 | 0.88 | KCNH3 (0.64) | KCNH3 | |
| SCHEMBL18671546 | 0.87 | — | — | |
| SCHEMBL12832765 | 0.85 | KCNH3 (0.62) | KCNH3 | |
| SCHEMBL12833289 | 0.83 | KCNH3 (0.59) | KCNH3 | |
| SCHEMBL12445526 | 0.83 | KCNH3 (0.59) | KCNH3 | |
| SCHEMBL12445649 | 0.83 | — | — | |
| SCHEMBL12833040 | 0.82 | — | — | |
| SCHEMBL12832771 | 0.82 | KCNH3 (0.58) | KCNH3 | |
| SCHEMBL12833290 | 0.82 | KCNH3 (0.58) | KCNH3 | |
| SCHEMBL16449250 | 0.82 | KCNH3 (0.57) | KCNH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603852-B2 | Treatment of obesity and pulmonary arterial hypertension | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9603852-B2 | Treatment of obesity and pulmonary arterial hypertension | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2488032-B1 | PROSTAGLANDIN TRANSPORTER INHIBITORS AND USES THEREOF | EINSTEIN COLL MED (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160113933-A1 | TREATMENT OF OBESITY AND PULMONARY ARTERIAL HYPERTENSION | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160113933-A1 | TREATMENT OF OBESITY AND PULMONARY ARTERIAL HYPERTENSION | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-8952150-B2 | Prostaglandin transporter inhibitors and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952150-B2 | Prostaglandin transporter inhibitors and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2015-02-10 | — | — | US | disclosed |
| WO-2014204895-A1 | TREATMENT OF OBESITY AND PULMONARY ARTERIAL HYPERTENSION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2011037610-A1 | PROSTAGLANDIN TRANSPORTER INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113933-A1 | TREATMENT OF OBESITY AND PULMONARY ARTERIAL HYPERTENSION | PTGIR, PTGIS, FABP4 | KCNH3 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.